Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus
Engelsk titel: GLP-1-based treatment of type 2 diabetes mellitus Läs online Författare: Knop FK ; Vilsböll T Språk: Dan Antal referenser: 40 Dokumenttyp: Översikt UI-nummer: 07061725

Tidskrift

Ugeskrift for Laeger 2007;169(22)2095-9 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

GLP-1 is secreted from the small intestine in response to ingestion of nutrients. It has a powerful insulinotropic effect and stimulates beta-cell growth and is therefore being developed for treatment of type 2 diabetes. The GLP-1 analogue, exenatide, is on the market in the USA as an add-on therapy. Another strategy to increase circulating GLP-1 is to inhibit the enzyme DPP-IV which degrades endogenous GLP-1. GLP-1-based therapy results in HbA1 c reductions of approximately 1 percent point, and the lack of serious side effects and the low risk of hypoglycaemic episodes are unique traits.